Authors’ response: “Brolucizumab-associated intraocular inflammation in Indian patients by VRSI study group”

Authors’ response: “Brolucizumab-associated intraocular inflammation in Indian patients by VRSI study group”

Saved in:

Bibliographic Details
Main Authors:	Manisha Agarwal, Alankrita Muralidhar, Debdulal Chakraborty, Mahesh P Shanmugam
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2025-06-01
Series:	Indian Journal of Ophthalmology
Online Access:	https://journals.lww.com/10.4103/IJO.IJO_2773_24
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Comment on “Brolucizumab-associated intraocular inflammation in Indian patients by VRSI study group”
by: Sabyasachi Sengupta, et al.
Published: (2025-06-01)

Discrepancies in choroidal thickness and brolucizumab intravitreal injection: Cause or effect of intraocular inflammation?
by: Sunny, Chi Lik Au
Published: (2024-10-01)

Preferred practice patterns of endophthalmitis management and prevention: A survey among the members of Vitreoretinal Society of India – Study by the VRSI study group
by: Deepanshu Agrawal, et al.
Published: (2025-06-01)

Brolucizumab versus aflibercept for recalcitrant diabetic macular edema in Indian real-world scenario – The BRADIR study
by: Debdulal Chakraborty, et al.
Published: (2024-12-01)

Proactive Post-Injection Monitoring in Brolucizumab Therapy: A Study on Intraocular Inflammation and Treatment Outcomes
by: Soman M, et al.
Published: (2025-04-01)

Risk factors for emerging intraocular inflammation after intravitreal brolucizumab injection for age-related macular degeneration.
by: Ryo Mukai, et al.
Published: (2021-01-01)

A rare case of Stenotrophomonas maltophilia endogenous endophthalmitis in pediatric age group
by: Tanya Jain, et al.
Published: (2024-12-01)

Contralateral Effect following Intravitreal Brolucizumab Injection in Diabetic Macular Edema
by: Somnath Chakraborty, et al.
Published: (2022-01-01)

Brolucizumab results and adverse visual outcomes study: A single-center real-world Indian experience
by: Ramesh Venkatesh, et al.
Published: (2025-06-01)

Safety and effectiveness of brolucizumab in patients with neovascular age-related macular degeneration: A phase IV study from India
by: Asim K Ghosh, et al.
Published: (2025-06-01)

Efficacy of Intravitreal Brolucizumab Switch in Pachychoroid Neovasculopathy
by: Nicolò Ribarich, et al.
Published: (2025-07-01)

Bilateral primary vitreoretinal lymphoma masquerading as fungal endophthalmitis- a case report
by: Manisha Agarwal, et al.
Published: (2024-12-01)

Experience with Brolucizumab Treatment of Neovascular Age-Related Macular Degeneration
by: M. V. Budzinskaya, et al.
Published: (2023-01-01)

The First Results of a Full Loading Dose of Brolucizumab in the Treatment of DME
by: R. N. Amirkulieva, et al.
Published: (2023-12-01)

Changes in Aqueous Humor Cytokine Profile Following Intravitreal Brolucizumab Injection
by: Ruamviboonsuk V, et al.
Published: (2025-02-01)

Brolucizumab Monotherapy in Idiopathic Polypoidal Choroidal Vasculopathy:A Case Report
by: Mohan S, et al.
Published: (2025-01-01)

Brolucizumab for the Treatment of Diabetic Macular Edema: An Optical Coherence Tomography-Based Analysis
by: Marco R. Pastore, et al.
Published: (2024-12-01)

Unilateral Crystalline Vitreoretinopathy: A Rare Entity Associated with Intraocular Inflammation
by: Kaustubh B. Harshey, et al.
Published: (2015-01-01)

Case series: Brolucizumab efficacy and safety in treating neovascular age‐related macular degeneration
by: Linling Cheng, et al.
Published: (2025-03-01)

Initial experience with brolucizumab for neovascular age-related macular degeneration (nAMD) in India – Multicentric, real-world study
by: Deependra Vikram Singh, et al.
Published: (2024-12-01)

The Effect of a Loading Dose Regimen in the Switch to Brolucizumab for Patients with Aflibercept-Resistant nAMD
by: Hiroyuki Kamao, et al.
Published: (2024-01-01)

Efficacy and safety of brolucizumab every 6 weeks induction therapy for neovascular age-related macular degeneration
by: Shigeru Honda, et al.
Published: (2025-02-01)

Efficacy & safety of brolucizumab 6.0 mg versus 3.6 mg in diabetic macular edema
by: Sanjay Kumar Mishra, et al.
Published: (2025-01-01)

Novel Resolution of Multilayered Pigment Epithelial Detachment Lamellae Following Brolucizumab Treatment—A Case Report
by: Unnikrishnan Nair, et al.
Published: (2025-01-01)

Treatment of neovascular age-related macular degeneration: one year real-life results with intravitreal Brolucizumab
by: Settimio Rossi, et al.
Published: (2025-01-01)

The levels of evidence of articles published by Indian authors in Indian journal of plastic surgery
by: Nikhil Panse, et al.
Published: (2015-05-01)

Survival outcomes and prognosis predictors of uveal melanoma from Indian population
by: Payal N Shah, et al.
Published: (2025-08-01)

Author's Response to comment on: Association of eGFR with stages of diabetic retinopathy and age-related macular degeneration in an Indian population
by: Vidya Neelamegam, et al.
Published: (2025-01-01)

Dynamics of Inflammatory Factors in Aqueous Humor During Brolucizumab Treatment for Age-Related Macular Degenerations: A Case Series
by: Masaki Asakage, et al.
Published: (2025-02-01)

Comparison of OCT Angiography Parameters after Administration of Intravitreal Brolucizumab versus Ranibizumab in Exudative Age-related Macular Degeneration
by: Sanjitha Vilma Moses, et al.
Published: (2024-12-01)

Brolucizumab in patients with neovascular age-related macular degeneration: Real-life outcomes from a tertiary care eye hospital
by: Lorenzo Fabozzi, et al.
Published: (2024-11-01)

Intraocular Pressure-Lowering Effect of Intraocular Lens Refixation in Patients with Elevated Intraocular Pressure Due to Intraocular Lens Subluxation
by: Kentaro Iwasaki, et al.
Published: (2024-09-01)

Aflibercept high-dose (8mg) related intraocular inflammation (IOI) – a case series
by: Laura Hoffmann, et al.
Published: (2024-12-01)

Effectiveness and Safety of Intravitreal Brolucizumab for Diabetic Macular Edema After Vitrectomy: A Before-and-After Study at a Specialized Center in Japan
by: Saito K, et al.
Published: (2025-06-01)

Real-World Outcomes of Brolucizumab Treatment in Japanese Patients with Neovascular Age-Related Macular Degeneration: A 12-Month, Multicenter Study
by: Masayuki Ohnaka, et al.
Published: (2025-05-01)

Current Practice Pattern for Macular Hole Management
by: Manisha Agarwal, et al.
Published: (2015-04-01)

Poor uptake of fluorodeoxyglucose in positron emission tomography-computed tomography scan for intraocular choroidal melanoma in Asian Indian Eyes
by: Rahul Sharma, et al.
Published: (2016-01-01)

Two-Years Real-World Experience of a Tertiary Center with Intravitreal Brolucizumab Switch for Treatment of Exudative Neovascular Age-Related Macular Degeneration
by: Federico Beretta, et al.
Published: (2025-04-01)

Authors’ Response
by: Branko Beronja, et al.
Published: (2025-03-01)

Response of the author
by: ILIT FERBER
Published: (2021-01-01)